The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Early Phase 1

Completed

• Conditions: Healthy; Memory Impairment
• Interventions: Drug: AZD8529; Drug: Placebo to match AZD8529

• Registration Number: NCT00985933
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-09-25
• Study First Submitted QC: 2009-09-28
• Study First Posted: 2009-09-29
• Study Start: 2010-02
• Primary Completion: 2011-04
• Study Completion: 2011-04
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-03
• Last Update Posted: 2011-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Right handed
• 12th grade education or equivalent
• Able to read and write English as primary language

Exclusion Criteria

• History of head injury
• Substance abuse or dependence
• History of claustrophobia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	AZD8529	180 mg of AZD8529
1	Placebo to match AZD8529	180 mg of AZD8529
2	Placebo to match AZD8529	50 mg AD8529
3	AZD8529	Placebo
3	Placebo to match AZD8529	Placebo
2	AZD8529	50 mg AD8529

Primary Outcome Measures

Name	Time	Method
fMRI	3
Ketamine Infusion	3

Secondary Outcome Measures

Name	Time	Method
Clinician Administered Dissociative States Scale (CADSS)
Positive and Negative Syndrome Scale (PANSS)
Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events

Trial Locations

Locations (1)

Research Site; 🇺🇸 New Haven, Connecticut, United States